Institution Directory

Clinical trials at Johns Hopkins

Sites in Baltimore, MD

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 11:37 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1432

Shown on this page

Current sort

Live official records

Conditions: Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions: UGN-102; Drug
Lead sponsor: UroGen Pharma Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 16
States / cities: Tucson, Arizona • Loma Linda, California • San Diego, California + 11 more

Conditions: Alcohol Use Disorder
Interventions: cerebellar transcranial direct current stimulation; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 25 Years to 55 Years
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: NF1, Neurofibromatosis, Cutaneous Neurofibroma, Neurofibroma, Von Recklinghausen Disease, Neurofibromas
Interventions: Imlygic; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lipid Disorders and Lipid Measurement
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: Not listed
Enrollment: 5,051,467 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Biliary Tract Cancers
Interventions: mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)], Durvalumab, Tremelimumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Normal Pressure Hydrocephalus, Hakim Syndrome
Interventions: patients will receive NPH education, primary care physicians (PCPs) will receive professional NPH education, A community health worker will assist PCP; Other
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 65 Years and older
Enrollment: 660 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2032
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Diabetes Mellitus Type 2, Childhood-Onset
Interventions: Not listed
Lead sponsor: George Washington University; Other
Eligibility: 8 Years to 15 Years
Enrollment: 3,600 participants
Timeline: 2024 – 2028
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more

Conditions: Obesity and Overweight
Interventions: fMRI cue reactivity task, fMRI go no go task, Ad libitum meal test, Eating in the absence of hunger test; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 7 Years to 12 Years
Enrollment: 210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 4
States / cities: Baltimore, Maryland • Providence, Rhode Island • Seattle, Washington

Conditions: PMDD, Premenstrual Dysphoric Disorder (PMDD), Premenstrual Syndrome-PMS, Premenstrual Syndrome, Menstrual Cycle
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Absence Epilepsy, Ketogenic Dieting, Epilepsy, Absence
Interventions: Modified Atkins Diet, Absence epilepsy medications; Other · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 3 Years to 12 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Multiple Sclerosis
Interventions: Ublituximab, Ocrelizumab; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Stroke, Dyslexia, Acquired
Interventions: Phono-Motor Therapy, Semantic Feature Analysis; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 85 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Tallahassee, Florida • Baltimore, Maryland • West Orange, New Jersey

About this Johns Hopkins institution page

What this page lists: ClinicalTrials.gov records that list Johns Hopkins in Baltimore, MD as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Johns Hopkins

Filter and sort this campus

Live official records

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Cerebellar Involvement in Alcohol Use Disorder (AUD)

Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1

The Very Large Database of Lipids

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Addressing Health Disparities in Normal Pressure Hydrocephalus (NPH) in Maryland

DISCOVERY of Risk Factors for Type 2 Diabetes in Youth

Brain and Behavior Influences on Obesity Development From Infancy Through Childhood

Identification and Validation of Epigenetic Biomarkers of PMDD

Ketogenic Diet for New-Onset Absence Epilepsy

Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis

Acquired Dyslexia Modeling and Treatment

About this Johns Hopkins institution page